Cadila Healthcare is currently trading at Rs. 263.40, up by 1.75 points or 0.67% from its previous closing of Rs. 261.65 on the BSE.
The scrip opened at Rs. 257.50 and has touched a high and low of Rs. 265.60 and Rs. 254.40 respectively. So far 30924 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 352.30 on 01-Apr-2019 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 280.25 and Rs. 254.40 respectively. The current market cap of the company is Rs. 27113.82 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.20% and 7.80% respectively.
Zydus Cadila has launched a fast tracked programme to develop vaccine for the novel coronavirus, 2019-nCoV (COVID-19) based on two approaches. The first approach deals with development of a DNA vaccine against the major viral membrane protein responsible for the cell entry of the novel coronavirus, now called COVID-19. The second approach deals with development of a live attenuated recombinant measles virus vectored vaccine against COVID-19.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: